Prognostic Value of von Willebrand Factor, CD34, CD31, and Vascular Endothelial Growth Factor Expression in Women with Uterine Leiomyosarcomas

Journal of Surgical Oncology

Volumn 86, Issue 2, 2004, Pages 84-90

  Poncelet, Christophe ^a,b,d   Fauvet, Rafaelle ^a   Feldmann, Gérard ^a   Walker, Francine ^b   Madelenat, Patrick ^b   Darai, Emile ^a,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b BICHAT HOSPITAL   (France)

^c HÔPITAL TENON   (France)

^d INSERM   (France)

Author keywords

Angiogenesis; CD31; CD34; FvW; Leiomyoma; Leiomyosarcoma; Myometrium; VEGF

Indexed keywords

CD31 ANTIGEN; CD34 ANTIGEN; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; MICROVASCULATURE; MYOMETRIUM; PRIORITY JOURNAL; PROGNOSIS; SALPINGOOOPHORECTOMY; TUMOR VOLUME; UTERUS CANCER; UTERUS SARCOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD31; ANTIGENS, CD34; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LEIOMYOMA; LEIOMYOSARCOMA; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; UTERINE NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON WILLEBRAND FACTOR;

EID: 2342451974     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.20055     Document Type: Article

References (37)

1. Abulafia O, Triest W, Sherer D: Angiogenesis in squamous cell carcinoma in situ and microinvasive carcinoma of the uterine cervix. Obstet Gynecol 1996;88:927-932.
2. Abulafia O, Triest W, Sherer D: Angiogenesis in malignacies of the female genital tract. Gynecol Oncol 1999;72:220-231.
3. Bodner K, Bodner-adler B, Kimberger O, et al.: Evaluating prognostic parameters in women with uterine leiomyosarcoma. A clinicopathologic study. J Reprod Med 2003;48:95-100.
4. Bosari S, Lee AKC, Delellis RA, et al.: Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 1992;23: 755-761.
5. Buttram VC, Reiter RC: Uterine leiomyomata: Etiology, symptomatology, and management. Fertil Steril 1981;36:433-445.
6. Casey R, Rogers PAW, Vollenhoven BJ: An immunohistochemical analysis of fibroid vasculature. Hum Reprod 2000;15:1469-1475.
7. Chou C, Huang S, Tsai Y, et al.: Uterine leiomyosarcoma has deregulated cell proliferation, but not increased microvessel density compared with uterine leiomyoma. Gynecol Oncol 1997; 65:225-231.
8. Darai E, Bringuier AF, Walker-Combrouze F, et al.: CD31 expression in benign, borderline, and malignant epithelial ovarian tumors: An immunohistochemical and serological analysis. Gynecol Oncol 1998;71:122-127.
9. De Jong JS, Van Diest PJ, Baak JPA: Methods in laboratory investigation. Heterogeneity and reproducibility of microvessel counts in breast cancer. Lab Invest 1995;73:922-926.
10. Dellas A, Moch H, Schultheiss E, et al.: Angiogenesis in cervical neoplasia: Microvessel quantitation inprecancerous lesion and invasive carcinomas ith clinicopathological correlations. Gynecol Oncol 1997;67:27-33.
11. De Young BR, Wick MR, Fitzgibbon JF, et al.: CD31: An immunospecific marker for endothelial differentiation in human neoplasms. Appl Immunohistochem 1993;1:97-100.
12. Emoto M, Iwasaki H, Ishiguro M, et al.: Angiogenesis in carcinosarcomas of the uterus: Differences in the microvessel density and expression of vascular endothelial growth factor between the epithelial and mesenchymal elements. Hum Pathol 1999;30: 1232-1241.
13. Folkman J, Watson K, Ingber D, et al.: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339:58-61.
14. Folkman J: Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1957-1963.
15. Giatromanolaki A, Koukourakis MI, Theodossiou D, et al.: Comparative evaluation of angiogenesis assessment with anti-factor-VIII and anti-CD31 immunostaining in non small cell lung cancer. Clin Cancer Res 1997;3:2485-2492.
16. Giatromanolaki A, Sivridis E, Koukourakis M, et al.: Intratumoral angiogenesis: A new prognostic indicator for stage I endometrial adenocarcinomas? Oncol Res 1999;11:205-212.
17. Harrison-Woolrych ML, Sharkey AM, Stephen D, et al.: Localization and quantification of vascular endothelial growth factor messenger ribonucleic acid in human myometrium and leiomyomata. J Clin Endocrinol Metab 1995;80:1853-1858.
18. Hata K, Hata T, Lida K, et al.: Expression of thimitine phosphorylase in uterine sarcoma and uterine leiomyoma: Association with microvessel density and blood flow analysis. Ultrasound Obstet Gynecol 1997;10:54-58.
19. Hong T, Shimada Y, Uchida S, et al.: Expression of angiogenic factors and apoptotic factors in leiomyosarcoma and leiomyoma. Int J Mol Med 2001;8:141-148.
20. Horak E, Leek R, Klenk N, et al.: Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 1992;340:1120-1124.
21. Huang SC, Yu CH, Huang RT, et al.: Intratumoral blood flow in uterine myoma correlated with a lower tumor size and volume, but not correlated with cell proliferation or angiogenesis. Obstet Gynecol 1996;87:1019-1024.
22. Ishiwata I, Ishiwata C, Soma M, et al.: Tumor angiogenic activity of gynecologic tumor cell lines on the chorioallantoic membrane. Gynecol Oncol 1988;29:87-93.
23. Obermaier A, Kohlberger P, Bancher-Todesca D, et al.: Influence of microvessel density and vascular permeability factor/vascular endothelial growth factor expression on prognosis in vulvar cancer. Gynecol Oncol 1996;63:204-209.
24. Poncelet C, Madelenat P, Feldmann G, et al.: Expression of von Willebrand's factor, CD34, CD31, and vascular endothelial growth factor in uterine leiomyomas. Fertil Steril 2002;78:581-586.
25. Reynolds LP, Grazul-Bilska AT, Redmer DA: Angiogenesis in the corpus luteum. Endocrine 2000;12:1-9.
26. Risau W, Flamme I: Vasculogenesis. Annu Rev Cell Dev Biol 1995;11:73-91.
27. Schor AM, Pendleton N, Pazouki S, et al.: Assessment of vascularity in histological sections: Effects of methodology and value as an index of angiogenesis in breast tumours. Histochem J 1998;30:849-856.
28. Smith SK: Regulation of angiogenesis in the endometrium. Trends Endocrinol Metab 2001;12:147-151.
29. Sobin L, Wittekind C: UICC TNM classification of malignant tumours, 5th edn. Saint-Etienne, Cassini: French translation. 1998.
30. Tjalma W, Van Marck E, Weyler J, et al.: Quantification and prognostic relevance of angiogenic parameters in invasive cervical cancer. Br J Cancer 1998;78:170-174.
31. Tomlinson J, Barsky S, Nelson S, et al.: Different patterns of angiogenesis in sarcomas and carcinomas. Clin Cancer Res 1999; 5:3516-3522.
32. Traweek S, Kandalaft P, Mehta P, et al.: The human hematopoietic progenitor cell antigen (CD34) in vascular neoplasia. Am J Clin Pathol 1991;96:25-31.
33. Van De Rijn M, Hendrickson M, Rouse R: CD34 expression by gastrointestinal tract stromal tumors. Hum Pathol 1994;25:766-771.
34. Vermeulen P, Gasparini G, Fox S, et al.: Quantification of angiogenesis in solid human tumors: An international consensus on the methodology and criteria for evaluation. Eur J Cancer 1996:32:2474-2484.
35. Weidner N, Semple J, Welch W, et al.: Tumor angiogenesis and metastasis: Correlation in invasive beast carcinoma. N Engl J Med 1991;324:1-8.
36. Weidner N, Folkman J, Pozza F, et al.: Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-1887.
37. Weidner N: Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995;147:9-19.